((S)-1-{(2S,4S)-2-[5-(4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester | 1335315-65-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ((S)-1-{(2S,4S)-2-[5-(4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
• 英文别名: methyl N-[(2S)-1-[(2S,4S)-2-[5-[4-[4-[2-[(2S,4S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-4-methylpyrrolidin-2-yl]-3H-benzimidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-4-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• CAS: 1335315-65-5
• 化学式: C₄₆H₅₆N₈O₆
• 分子量: 817.001
• InChiKey: UPGJLYYUAKKKAD-JVGMIBGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  60
• 可旋转键数：
  13
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  MOC-L-缬氨酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 碳酸氢钠 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 20.22h， 生成 ((S)-1-{(2S,4S)-2-[5-(4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
  参考文献：
  名称：

  [EN] ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
  [FR] ANALOGUES POUR TRAITER OU PRÉVENIR LES INFECTIONS À FLAVIVIRUS

  摘要：

  本文所述的以I式表示的化合物或其药用盐，其中A、B、B'、X、Y、R1、R2、R2'、R3、R3'、R4、R4'、R5、R5'、m、n或p如本文所定义，对治疗黄病毒科病毒感染有用。

  公开号：

  WO2011119853A1

文献信息

• Analogues for the treatment or prevention of flavivirus infections
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US08779156B2

  公开（公告）日：2014-07-15

  Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R1, R2, R2′, R3, R3′, R4, R4′, R5, R5′, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

  公式I所代表的化合物或其药学上可接受的盐，其中A、B、B'、X、Y、R1、R2、R2'、R3、R3'、R4、R4'、R5、R5'、m、n或p的定义如本文所述，可用于治疗黄病毒科病毒感染。
• ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20130090351A1

  公开（公告）日：2013-04-11

  Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R 1 , R 2 , R 2 ′, R 3 , R 3 ′, R 4 , R 4 ′, R 5 , R 5 ′, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

  公式I所代表的化合物或其药学上可接受的盐，其中A、B、B'、X、Y、R1、R2、R2'、R3、R3'、R4、R4'、R5、R5'、m、n或p的定义如本文所述，对于治疗黄病毒科病毒感染是有用的。
• Benzimidazole-containing HCV NS5A inhibitors: Effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency
  作者：James A. Henderson、Darius Bilimoria、Monica Bubenik、Caroline Cadilhac、Kevin M. Cottrell、Evelyne Dietrich、Francois Denis、Nigel Ewing、Guy Falardeau、Simon Giroux、Ronald Grey、Lucille L’Heureux、Bingcan Liu、Nagraj Mani、Mark Morris、Olivier Nicolas、Oswy Z. Pereira、Carl Poisson、B. Govinda Rao、T. Jagadeeswar Reddy、Subajini Selliah、Rebecca S. Shawgo、Louis Vaillancourt、Jian Wang、Constantin G. Yannopoulos、Nathalie Chauret、Francoise Berlioz-Seux、Laval C. Chan、Sanjoy K. Das、Anne-Laure Grillot、Youssef L. Bennani、John P. Maxwell

  DOI：10.1016/j.bmcl.2014.12.045

  日期：2015.2

  The treatment of HCV with highly efficacious, well-tolerated, interferon-free regimens is a compelling clinical goal. Trials employing combinations of direct-acting antivirals that include NS5A inhibitors have shown significant promise in meeting this challenge. Herein, we describe our efforts to identify inhibitors of NS5A and report on the discovery of benzimidazole-containing analogs with subnanomolar potency against genotype 1a and 1b replicons. Our SAR exploration of 4-substituted pyrrolidines revealed that the subtle inclusion of a 4-methyl group could profoundly increase genotype 1a potency in multiple scaffold classes. (C) 2014 Elsevier Ltd. All rights reserved.
• US8779156B2
  申请人：——

  公开号：US8779156B2

  公开（公告）日：2014-07-15